Ruti Aga's Six Years: A Glucocorticoid, a Forged Prescription, and the Arithmetic the Media Skipped

10 September appears twice in the Athletics Integrity Unit's statement — once as the start of the provisional suspension, once as the start of a six-year ban. Same date both times. The paperwork was tidied; the athlete gained nothing.

The number I distrusted first was not the date. It was the six. In doping cases a ban length is not a mood, it is arithmetic. When a report says a marathoner got six years for a “fake prescription”, the question is not whether the punishment is heavy or light — it is which two numbers add up to six.

Who wrote the prescription? A family member posing as a doctor, with no medical registration, who claimed to have used “an old prescription pad from a former workplace.” The clinic whose name was on that pad said it had issued no such thing. That is not a filing error. That is a portrait of medical governance in a sport where an elite runner's knee was being managed by a relative instead of a credentialed physician.

My interest here is not that another athlete was caught. It is that the reporting carries a technical error which happens to be the password to the whole case.

Context

Ruti Aga is a 32-year-old Ethiopian road runner, a 2:18–2:20 class marathoner. My own notes carry her Berlin 2026 second place (around 2:18:34) and her 2026 Tokyo Marathon title (around 2:20:40) — those come from my records, not from the AIU statement, so file them under pending verification. What the source does state: three second-place finishes at World Marathon Majors.

In March she won a half marathon in China. An in-competition sample returned methylprednisolone. The defence was a knee injury, supported by a prescription. The AIU found the prescription forged. The outcome: two years for the presence violation, four for tampering, six in total, effective from 10 September.

Now the correction the media skipped. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (S1). Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes.

That single sentence reorganises the case. If the substance is prohibited only in-competition, the case turns on route and timing, not on “steroid use.” A therapeutic knee injection out of competition is entirely legal; it becomes a violation only when residues are present in-competition. A road race's testing window opens at 23:59 the day before the race, which is precisely how an injection given days earlier gets caught.

The core

The arithmetic: 2 + 4 = 6

Six years is not one decision, it is two findings stacked. Two for presence, four for tampering. Four is the Code's standard tampering sanction. Two for presence matches a panel that did not find intent but also refused the no-significant-fault mitigation that would have cut the period further.

That is the real story. With genuine medical records the defence had a legitimate path — route, timing, medical necessity. The moment the prescription was fabricated, the athlete destroyed the only defence that could have worked. The four years are the price of that act, not of the drug.

Note also that the panel did not use the tampering to aggravate the presence sanction. Two and four stand apart. Technically clean; logically odd, since forged documentation is itself circumstantial evidence of concealment. That is how the Code's machinery works — each charge climbs its own ladder.

Three verification failures in one document

A forged document usually fails in more than one place. This one failed in three.

The clinic named on the prescription could not be found. The person who wrote it was not a registered physician — he was a family member. And the “old pad” defence was rejected by the very clinic whose name was printed on it.

Three independent verification failures — that is not a measure of carelessness, it is a measure of the environment in which an athlete believes paper is paper and nobody checks. The AIU checked. That is the entire event.

Here I have to restrain a reflex. A clean audit tempts you to write that the previous chroniclers were negligent. The cause is structural: no dedicated athletics beat covers these races, agency copy is pasted from agency copy, and there is no public audit of medical support in Ethiopian road running. The failure belongs to the system that let a relative stand where a team doctor should stand.

The knee is the root, and the root is systemic

Chronic knee pathology is a professional risk in marathoners, not an exception. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports medicine, which is exactly why the defence sounds plausible at first hearing.

Its plausibility is the bitter part: a treatment that genuinely happened would have left genuine records. Real records mean a TUE application, or at minimum observance of the route-specific washout period. Neither appears to have happened. A prescription was manufactured instead.

That tells me there was no credentialed team physician. Nobody was saying: this injection is fine until fourteen days out, not after. In East African road-running clusters that gap is normal — agent, coach, physio and “doctor” dissolve into one informal network. Formal governance arrives with the AIU notice.

An economic logic attaches here that nobody counts. Appearance fees, prize money and agent commissions all depend on running. A knee injury ends a season, and a season is income. The incentive to mask pain is less a moral weakness than an economic squeeze, and glucocorticoids are the cheapest, most available tool for it.

China's label circuit: income tier and testing frontier

The source does not name the March race. The inference is straightforward: an AIU test implies a World Athletics Label race with an elite women's field and in-competition testing.

China's label calendar has become a distinct income tier for East African marathoners between Majors — decent appearance fees, thin competitive pressure. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races.

Where money is dense and testing is dense, cases will be dense. That is not prophecy, it is arithmetic.

What survives: Tokyo 2026

The 2026 Tokyo Marathon title is not automatically erased. The violation is anchored to a March race; absent a finding of earlier use, results before that date stand. The source does not state the disqualification scope.

My working assumption: the March result and its prize money are voided, because AIU practice disqualifies the competition where the sample was collected. That is an inference, not a stated fact. Ranking points from that date forward should be void too.

Her record is now bifurcated: a Major title and three Major second places on one side; a six-year ban on the other. The first says she was genuinely elite. The second makes her commercially radioactive in a sport where distance-running sponsorship is already thin.

The age curve, and the question the report never asks

At 32, a six-year ban means returning at roughly 38. Ethiopian women's marathon depth means a 2:18 performer is not automatically selectable; a 38-year-old returnee with a doping record is effectively unselectable.

The sanction is six years on paper and career-terminal in effect. The distinction matters, because it tells you what the sanction is for — rehabilitation or deterrence. In road running the answer is usually deterrence.

Now the empty space that is my professional complaint. There is not one performance number in this story. No time for the Chinese half marathon, no splits, no field strength, not even the year. If I wrote that her form was good because she won, I would be fabricating data. Winning is a result, not form; form requires a clock, and no clock was given.

For years I have worked live timing desks on road races and major events. At the Paris 2026 javelin final I saw the feed duplicate Neeraj Chopra's third throw as 89.45m and corrupt the graphics. Since then my rule is: three sources, one question — who is actually doing the work? Primary sensor, official log, manual backup. Apply it here and the answer is: the primary source is the AIU statement; the second source is absent; so is the third. Where two and three are missing, you can repeat an official claim, you cannot audit it.

The contrarian read

Six years for a glucocorticoid invites the reflex that something is disproportionate. Glucocorticoids are not the long-residue anabolic drugs; this is a painkiller.

But when I opened the arithmetic I found no anomaly. Two and four both sit inside the Code's standard ranges. The disproportionality I was hunting for is not in the drug. It is in the document.

My honest report: the accepted number survives scrutiny. Six years is correct. What is wrong is the description of the substance — and that error sits in the reporting, not the ruling.

The counter-intuitive point lies elsewhere. There is no proven endurance benefit from glucocorticoids. They reduce inflammation, suppress pain, and perhaps drag an injured runner to a start line. The substance that triggered this machinery does not build capacity; it builds tolerance. The violation here is not performance enhancement. It is verification destroyed.

It is easy to conclude that the AIU came down hard on an African road runner. I will not deny that reading, but I cannot prove it either, because I lack the comparison set — how many tampering cases, in which countries, at what ratio, over five years. Where there is no data, I do not write a conclusion. What I can write: sanction counts measure governance weakness, not the volume of cheating. Where testing is dense, cases surface. That is sampling, not geography.

And one unheard side. The statement names the family member who wrote the prescription. It says nothing about the agent or management. Somebody advised the document, somebody accepted it, somebody passed it to the AIU. In a system where a prescription gets forged, the athlete's role is usually smaller than the entourage's. No charge was brought. That gap matters as much as the filled-in parts.

Forward signal

The next fight in anti-doping will be fought on paper, not in sample bottles. The last decade was detection — passports, biological profiling, re-tests. The next is verification: does the clinic exist, is the prescriber registered, is the TUE real. Athletes still assuming an old prescription pad will save them are already in the queue.

One question remains, and it belongs to administrators rather than arbitrators: who is treating these knees? Until that answer has a credentialed name attached, we will keep finding prescriptions — sometimes from a relative, sometimes from a clinic that exists on paper and nowhere else.